- Molecular NameAltretamine
- SynonymAltretaminum [INN-Latin]; HEXAMETHYLMELAMINE; HMM; HTM; HXM
- Weight210.285
- Drugbank_IDDB00488
- ACS_NO645-05-6
- Show 2D model
- LogP (experiment)2.73
- LogP (predicted, AB/LogP v2.0)2.35
- pkaN/A
- LogD (pH=7, predicted)2.27
- Solubility (experiment)0.091 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-2.58
- LogSw (predicted, AB/LogsW2.0)0.22
- Sw (mg/ml) (predicted, ACD/Labs)0.34
- No.of HBond Donors0
- No.of HBond Acceptors6
- No.of Rotatable Bonds3
- TPSA48.39
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn antineoplastic agent. It is used to treat refractory ovarian cancer.
- Absorption_valueN/A
- Absorption (description)Altretamine is rapidly and well absorbed after oral administration and quickly distributed to tissues with a high lipid component.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding94.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmIt is rapidly demethylated in the liver to pentamethylmelamine and other metabolites that are excreted in urine. Formaldehyde is also produced which is subsequently oxidised to carbon dioxide and expired. Other metabolites include dimethylmelamine, monomethylmelamine, trimethylmelamine and melamine, and these have been detected in urine. No parent drug has been detected in urine. Metabolism is catalysed by cytochrome P450 enzymes. Accumulation in plasma has not been observed with multiple dosing.
- Half life4.7~10.2 h
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A